References
- de Gramont A , FigerA, SeymorM et al.: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.J. Clin. Oncol.18(16) , 2938–2947 (2000).
- Saltz LB , CoxJV, BlankeC et al.; Irinotecan Study Group: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N. Engl. J. Med.343(13) , 905–914 (2000).
- Hurwitz H , FehrenbacherL, NovotnyW et al.: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.N. Engl. J. Med.350(23) , 2335–2342 (2004).
- Siena S , CassidyJ, TaberneroJ et al.: Randomized Phase III study of panitumumab (pmab) with FOLFOX4 compared with FOLFOX4 alone as firstline treatment (tx) for metastatic colorectal cancer (mCRC): PRIME trial. Presented at: 2010 Gastrointestinal Cancers Symposium. FL, USA, 22–24 January (2010) (Abstract 38).
- Zarate R , RodriguezJ, BandresE et al.: Oxaliplatin, irinotecan and capecitabine as first-line therapy in metastatic colorectal cancer (mCRC): a dose-finding study and pharmacogenomic analysis.Br. J. Cancer102 , 987–994 (2010).
References
- Sauer R , BeckerH, HohenbergerW et al.: Preoperative versus postoperative chemoradiotherapy for rectal cancer.N. Engl. J. Med.351(17) , 1731–1740 (2004).
- Gérard JP , ConroyT, BonnetainF et al.: Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3–4 rectal cancers: results of FFCD 9203. J. Clin. Oncol.24(28) , 4620–4625 (2006).
- Cecchin E , AgostiniM, PucciarelliS et al.: Tumor response is predicted by patient genetic profile in rectal cancer patients treated with neo-adjuvant chemo-radiotherapy.Pharmacogenomics J. DOI: 10.1038/tpj.2010.25 (2010) (Epub ahead of print).
References
- Linardou H , DahabrehIJ, KanaloupitiD et al.: Assessment of somatic K-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer.Lancet Oncol.9(10) , 962–972 (2008).
- Chin LJ , RatnerE, LengS et al.: A SNP in a let-7 microRNA complementary site in the KRAS 30 untranslated region increases non-small cell lung cancer risk.Cancer Res.68 , 8535–8540 (2008).
- Grazianio F , CanestrariE, LoupakisF et al.: Genetic modulation of the Let-7 microRNA binding to KRAS 3´-untranslated region and survival of metastatic colorectal cancer patients treated with salvage cetuximab-irinotecan. Pharmacogenomics J. DOI: 10.1038/tpj.2010.9 (2010) (Epub ahead of print).
References
- Linardou H , DahabrehIJ, KanaloupitiD et al.: Assessment of somatic K-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer.Lancet Oncol.9(10) , 962–972 (2008).
- Amado RG , WolfM, PeetersM et al.: Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer.J. Clin. Oncol.26(10) , 1626–1634 (2008).
- Jacobs B , De Roock W, Piessevaux H et al.: Amphiregulin and epiregulin mRNA expression in primary tumors predicts outcome in metastatic colorectal cancer treated with cetuximab. J. Clin. Oncol.27(30) , 5068–5074 (2009).
- Di Nicolantonio F , MartiniM, MolinariF et al.: Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.J. Clin. Oncol.26(35) , 5705–5712 (2008).
- Tabernero J , CervantesA, RiveraF et al.: Pharmacogenomic and pharmacoproteomic studies of cetuximab in metastatic colorectal cancer: biomarker analysis of a Phase I dose-escalation study.J. Clin. Oncol.28(7) , 1181–1189 (2010).
- Roca JM , AlonsoV, PericayC et al.: Cetuximab given every 2 weeks plus irinotecan is an active and safe option for previously treated patients with metastatic colorectal cancer.Chemotherapy56(2) , 142–146 (2010).
- Mrabti H , De la Fouchardiere C, Desseigne F et al.: Irinotecan associated with cetuximab given every 2 weeks versus cetuximab weekly in metastatic colorectal cancer. J. Cancer Res. Ther.5(4) , 272–276 (2009).